Laurion Capital Management LP Mirati Therapeutics, Inc. Transaction History

Laurion Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $429,422 - $576,712	-3,250 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$144.0 - $179.73 $468,000 - $584,122	3,250 New	3,250 $525,000
Q3 2019 Nov 13, 2019	SELL	$77.91 - $109.6 $2.07 Million - $2.91 Million	-26,545 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$59.49 - $104.71 $1.03 Million - $1.81 Million	17,240 Added 185.28%	26,545 $2.74 Million
Q1 2019 May 08, 2019	BUY	$43.65 - $78.95 $406,163 - $734,629	9,305 New	9,305 $682,000
Q2 2018 Aug 13, 2018	SELL	$26.05 - $52.4 $906,592 - $1.82 Million	-34,802 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$17.2 - $34.95 $598,594 - $1.22 Million	34,802 New	34,802 $1.07 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.